Suggested remit: To appraise the clinical and cost effectiveness of depemokimab within its marketing authorisation for severe eosinophilic asthma in people 12 years and over.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6447
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 December 2025 | Note - Note added to the project documents |
| 11 June 2025 | Invitation to participate |
| 12 March 2025 - 09 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6447 |
| 12 March 2025 - 09 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6447 |
| 12 March 2025 | In progress. Scoping commencing |
| 12 December 2024 | Referral |
| 04 November 2024 | Note - Note added to the project documents |
| 27 August 2024 | Note - Note added to the project documents |
| 23 May 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 23 May 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual